Medically reviewed by Drugs.com. Last updated on Aug 17, 2020.
(FER ik sub SULL fate)
- Monsel's Solution
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Astringyn: 259 mg/g (8 g) [contains benzalkonium chloride]
Monsels Ferric Subsulfate: (8 mL, 60 mL)
Brand Names: U.S.
- Monsels Ferric Subsulfate
- Hemostatic Agent
Causes agglutination of surface proteins resulting in hemostasis
Onset of Action
Hemostasis: ≤20 seconds
Use: Labeled Indications
Hemostatic in minor surgical procedures
There are no contraindications in the manufacturer’s labeling.
Hemostasis: Topical: Apply evenly to wound
Refer to adult dosing.
Topical: For external use only. Apply to wound using cotton applicator/swab. Avoid contact with eyes.
Store at controlled room temperature. Avoid heat and light.
There are no known significant interactions.
Frequency not defined.
Dermatologic: Skin hyperpigmentation (application site)
Concerns related to adverse effects:
• Hyperpigmentation: May cause heavy pigmentation at application sites, which may result in histologic artifacts (upon rebiopsy) or in radiographic artifacts.
• Appropriate use: For external use only. If inadvertent ocular administration occurs wash eye(s) immediately with large amounts of water or normal saline for approximately 15 to 20 minutes or until no evidence of solution remains.
Hemostasis at site of application.
Ferric subsulfate is used as a hemostatic agent following cervical biopsies (Manca 1997; Tam 2005). May cause vaginal pain if leakage of solution occurs (Tam 2005). A case report also describes use following a miscarriage; fertility was not impaired and a successful pregnancy occurred 7 months later (Disu 2007).
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.